





Background: Breast cancer is the most common cancer among women in the US: annually > 230,000 women are diagnosed and > 40,000 die. Although breast cancer screening (BCS) is a covered benefit and associated with a reduction in breast cancer, mortality, a large percentage of the population are not screened. 
Methods: Women 52-74 years old enrolled continuously in the (Managed Care Organization) MCO between October 1, 2014-December 31, 2016 were included in the analysis: 3,624 were BCS utilizers and 3,298 were non-utilizers. I used the Behavioral Model of Health Care Utilization framework to identify predictors of BCS utilization, including predisposing (e.g., age group), enabling (e.g., area of residence), and need-related (e.g., smoking) factors. Differences between groups were assessed using chi-square and logistic regression analyses. 
Results:  Overall, mean age of the women was 59 (±4) years, 20% were African American and 12% were Hispanic. Approximately 5% had family history of breast cancer, 23% were from rural areas, 39% had 3-5 chronic health conditions, 10% were obese, 15% were smokers, and 48% were non-BCS utilizers.  Results showed utilizers were more likely to be African American (OR: 1.28; 95%CI: 1.12-1.47), Hispanic (OR: 1.88; 95%CI: 1.51-2.35), have a family history (OR: 6.95; 95%CI: 4.94-9.83), smoke (OR: 1.20; 95%CI: 1.04-1.39), and had more PCP visits (OR: 1.02; 95%CI: 1.00-1.03). Women residing in rural areas (OR: 0.77; 95%CI: 0.68-0.88), Southwest PA (OR: 0.73; 95%CI: 0.61-0.87), and with no chronic health conditions (OR: 0.30; 95%CI: 0.21-0.42) were less likely to be utilizers. 
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1.1	breast cancer in the united states: Public health significance
Breast cancer is the most common cancer among women in the United States regardless of race or ethnicity  ADDIN EN.CITE [1-3]. According to the Surveillance Epidemiology and End Results Program (SEER), 230,815 women were diagnosed with breast cancer in 2013 [4]. Breast cancer accounts for 15% of all new cancer cases in the United States with an estimated 252,710 new cases in 2017 [4].  Furthermore, the Centers for Disease Control and Prevention (CDC) and SEER estimated that 40,610 deaths will result from breast cancer in 2017, which is 6.8% of all deaths  ADDIN EN.CITE [1, 2, 4]. The United States Cancer Statistics: 1999-2014 Incidence and Mortality Web-Based Report (USCS) combines cancer registry data from CDC’s National Program of Cancer Registries and the National Cancer Institute’s SEER data to provide national statistics on cancer and cancer mortality. The dataset contains over 22 million cancer cases across the United States, the District of Columbia, and Puerto Rico. Analyses of these data indicate that 12.4% of women born in the United States today will develop breast cancer over the course of their lives; in other words, 1 in 8 women will develop breast cancer at some point in their life [4]. Breast cancer is also the second leading cause of cancer related deaths after lung cancer among Caucasian, African American, and Asian/Pacific Islander women in the United States, first among Hispanic women, and third among American Indian and Alaska Native women [2]. 
Breast cancer screening is a method to find breast cancer before there are any signs of it. The goal of screening is to find cancer early which allows for easier treatment and higher chance of survival. Pace and colleagues conducted a meta-analysis study of 5 different meta-analyses on breast cancer mortality and breast cancer screening published after 2006 and also analyzed the risk and benefits of breast cancer screening using 48 different research articles from 1960 to 2000  ADDIN EN.CITE [5]. Pace et al. 2014 found that the benefits of breast cancer screening through mammography were a 19% overall reduction in breast cancer mortality and a 15% reduction in mortality in women in their 40s and 32% reduction for women in their 60s  ADDIN EN.CITE [5]. This reduction in breast cancer mortality can be attributed to the lower cost of breast cancer treatment and milder forms of treatment for treating an earlier stage of breast cancer compared to a later stage. 
1.2	Cost of breast cancer screening
The cost of breast cancer treatment varies by the stage of the cancer at diagnosis and type of cancer. Blumen et al. 2016 conducted a study of 8,360 women selected from the Truven Healthcare MarketScan commercial claims database diagnosed with 0, I/II, III, or IV stage breast cancer [6]. The insurance claims were calculated per patient for twenty four months after initial diagnosis [6]. The cost was found to increase with the later stage diagnosis of breast cancer compared to early stage for a total of $71,909, $97,066, $159,442, and $182,655 per individual for stages 0, I/II, III, IV, respectively [6]. Mariotto et al. 2011 conducted a study based on SEER-Medicare linked data claims to analyze the cost of cancer in the United States in individuals 65 years and older with cancer at various stages along with initial, remission, and last year of life costs  ADDIN EN.CITE [7]. In 2010, it was estimated that the national cost of cancer was $124.57 billion and breast cancer was the highest cost estimate at $16.50 billion  ADDIN EN.CITE [7]. 
The cost per person for breast cancer screening depends on the type of screening received. In 2011, LeMasters and colleagues conducted a retrospective study on 2,020 women across the United States through the Medical Expenditure Panel Survey (MEPS) to determine the cost of a mammogram screening  ADDIN EN.CITE [8]. MEPS selects participants to participate in multiple interviews over two years on the household component (HC) which contains demographics, health conditions, health status, use of medical services, charges and source of payment, access to care, health insurance coverage, income, and employment [9]. Participants are selected based on their participation in the prior year’s National Health Interview Survey (NHIS) and minority groups (Hispanics, Black, American Indian, Alaska Native, multiple races, Asian, Hawaiian, and Pacific Islander) are oversampled [9].They reported that a mammogram will cost $266 out of pocket, on average, for women without health care, although some discounts may be available  ADDIN EN.CITE [8]. For women without insurance, a clinical breast examination would cost approximately $47  ADDIN EN.CITE [10] and a breast magnetic resonance imaging (MRI) would cost $966 [11].  
The cost of breast cancer screening in the United States also varies because different providers follow different screening guidelines. O’Donoqhue and colleagues developed a simulation model to assess the cost of screening based on different guidelines, including: annual (40-84 years old), biennial (50-69 years old), and USPSTF guidelines (biennial 50-74 years old; personalized <50 and >75 years old) [12]. Using Medicare reimbursement rates for insurance companies (what an insurance company gets back from Medicare to cover the cost of a mammogram for a client) to determine the cost of mammography per woman, the authors estimated that the total cost of screening 85% of women participating in the programs was $10.1 billion for annual screening, $2.6 billion for biennial screening, and $3.5 billion for USPSTF guidelines [12]. 
1.3	Frequency and relative benefits of breast cancer screening
The usage of mammogram screening varies by the different techniques such as mammography, clinical examinations, and breast MRIs. According to the CDC, in 2015 64% of women aged 40 years and older in the general population in the United States had received a mammogram within the past two years [13]. Provencher et al. 2016 conducted a study in Quebec, Canada on the usefulness of clinical breast exams in breast cancer detection compared to mammography  ADDIN EN.CITE [14]. 6333 patients who were treated for breast cancer between 1999 and 2010 and their medical records examined to determine how the breast cancer was found  ADDIN EN.CITE [14]. Their results showed that 36.5% of cancers were detected by mammography alone, 54.8% detected by mammography and clinical breast examination, and 8.7% detected by clinical breast examination alone  ADDIN EN.CITE [14]. Their results also showed that invasive and aggressive tumors were more likely to be diagnosed with clinical breast examination alone than mammography  ADDIN EN.CITE [14]. A breast MRI is less commonly used for basic diagnostic screening due to its high cost [15]. However, it is used for women at high risk for breast cancer due to family history, determining the extent of breast cancer after a new diagnosis, further evaluation of abnormalities seen on a mammogram, and evaluation of breasts after surgery and chemotherapy to ensure that the cancer has been completely removed [15]. 
A 2016 study by DeSantis et al. based on data from the National Cancer Institute, CDC, and the North American Association of Central Cancer Registries on the general population in America reported that 11.1% of African American women developed breast cancer in their lifetime whereas 13.1% of Non-Hispanic White women did  ADDIN EN.CITE [16]. DeSantis and colleagues found that a delay in preventative screening leads to later stage diagnosis among minority women and an overall decrease in 5-year relative survival rate  ADDIN EN.CITE [16]. The study also stated that later stage diagnosis among black women has been attributed to lower frequency of mammograms and longer intervals between mammograms  ADDIN EN.CITE [16]. Lower stage-specific survival has been explained by unequal access to and receipt of prompt, high-quality treatment among black women compared with Caucasian women  ADDIN EN.CITE [16]. A 2015 study in Winston-Salem, North Carolina followed 191 women after early stage breast cancer treatment found that African American women were 3 times more likely to report cost, transportation, and anxiety over visiting a doctor barriers  ADDIN EN.CITE [17]. There is also a lack of timely follow-up in black women which is concerning since this population has a higher mortality rate than any other racial group  ADDIN EN.CITE [17]. According to the National Cancer Institute (NCI) which uses SEER data on the entire population in the United States, although Caucasian women have a higher incidence rate of breast cancer than blacks or Hispanic women, Caucasian women are also more likely to get screened and receive faster treatment than minorities  ADDIN EN.CITE [4, 18]. 
The National Cancer Institute explains that in addition to the low cost of a clinical breast exam, the exam is also fast (usually less than ten minutes) and non-invasive [19]. According to the American Cancer Society, a MRI is more likely to pick up smaller tumors than clinical breast exams and do not use radiation like mammograms do, but usually take longer (45 to 60 minutes) [20].  Mammography has many benefits including relative low cost (especially with insurance), fast examination time, and non-invasive procedure [21]. 
2.0 	Risk factors for breast cancer
Both genetic and environmental risk factors influence risk of developing breast cancer. Genetic risk factors are characteristics a person has that involves their genetics that puts them at a higher risk for developing a disease or trait. Genetic risk factors include family history of breast cancer, as well as variants in genes that are known to influence breast cancer susceptibility, such as the BRCA1 and BRCA2 mutations. Environmental risk factors are characteristics an individual has that are caused by the environment and not due to their biological make up. Environmental risk factors for breast cancer include age, alcohol consumption, smoking status, and diet. Some risk factors for breast cancer, such as obesity, compromise both genetic and environmental components. 
2.1	epidemiology of breast cancer
2.1.1	Non-genetic risk factors of breast cancer
2.1.1.1	Age
Age is a risk factor for breast cancer development. As a woman’s age increases, her risk of developing breast cancer also increases. SEER data from 2010 to 2014 on the general population in the United States shows that 25.8% of new breast cancer cases occur in women between ages 55 to 64 years [22]. The majority of new breast cancer cases (68.6%) occur after the age of 55 years [22]. Results from the same dataset indicates that the median age at diagnosis is 62 years and the median age of death is 68 years [22]. 

Table 1. Percentage of new breast cancer cases in the United States from 2010 to 2014 and the age group that they were diagnosed in.












Smoking has been associated as a risk factor for developing breast cancer. The U.S. Department of Health and Human Services released a report in 2014 describing the literature on the health consequences of smoking over the past 50 years [23]. Cigarettes contain tobacco which contains thousands of human carcinogens [23]. Smoking is typically associated with lung cancer development, heart disease, and respiratory disease, but has been thought to be associated with other cancers as well [23].  
Both women who are current smokers and women who have quit smoking are at a higher risk of developing breast cancer than a woman who has never smoked cigarettes. Gaudet et al. 2013 conducted a cohort study on 73,388 women in the American Cancer Society’s Cancer Prevention Study II (CPS-II) which contained 3,721 invasive breast cancer cases over a 14 year period (1992 to 2005)  ADDIN EN.CITE [24]. Participants (97% white) were retained in the study by completing a questionnaire every two years (response rate 86%) on smoking status, lifestyle, education, and mammogram status  ADDIN EN.CITE [24]. The incidence rate of breast cancer was calculated as hazard ratios (HR). The incidence rate of breast cancer was higher in current smokers (HR = 1.24, 95%CI = 1.07-1.42) and former smokers (HR = 1.13, 95%CI = 1.06-1.21) than in never smokers  ADDIN EN.CITE [24].  Gaudet et al. 2013 also conducted a meta-analysis that included their own data and an additional 15 studies and 991,100 women (31,198 breast cancer cases). The incidence rate of breast cancer was slightly higher in current (HR = 1.12, 95%CI = 1.07-1.42) and former smokers (HR = 1.09, 95%CI = 1.06-1.21) compared to never smokers  ADDIN EN.CITE [24]. 
Even if a woman is not directly smoking, she can still be at a higher risk of developing breast cancer. Passive smoking, or second hand smoke, is exposure to smoke when an individual has not smoked cigarettes. This can happen at home, work, or in a public area. Dossus et al. 2014 conducted a cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC) that involved 322,988 women of which 9,822 developed breast cancer and 183,608 were exposed to passive smoking (6,264 breast cancer cases). The study population collected from 1992 to 2000 and was primarily white Europeans currently living in Europe and contained 56.7% never smoker, 23.3% former smoker, and 20.0% current smoker. Data was also collected on passive smoking exposure, age at which smoking began, duration of smoking, amount of cigarettes per day, BMI, physical activity, age at menarche, menopausal status, and age at first full-term pregnancy. Dossus et al. 2014 showed that both active and passive smoking have an effect on breast cancer risk. Women who had never smoked and were not being exposed to passive smoke had a lower hazard ratio than those who were current (HR = 1.16, 95%CI = 1.05-1.28), former (HR = 1.14, 95%CI = 1.04-1.25), or exposed to passive smoke (HR = 1.10, 95%CI = 1.01-1.20). Additionally, Reynolds et al. 2004 conducted a cohort study in California from 1995 to 2000 containing 116,544 members of the California Teachers Study (CTS) who has no breast cancer at baseline in 1995  ADDIN EN.CITE [25]. In 2000, 2005 women from the cohort had developed breast cancer  ADDIN EN.CITE [25]. The cohort was 86.7% white with an average age of 54 years  ADDIN EN.CITE [26]. Reynolds et al. 2004 results show that current smokers had a higher hazard ratio than those who had never smoked/exposed to passive smoke (HR = 1.32, 95%CI = 1.10-1.57) and never smoked/never exposed to passive smoke (HR = 1.25, 95%CI = 1.02-1.53)  ADDIN EN.CITE [25]. Although not as strong of results as the Dossus et al. 2014 study, there is still a mild difference between active and passive smoke exposure. 
2.1.1.3	Obesity
The CDC’s National Center for Health Statistics utilizes data from the National Health and Nutrition Examination Survey (NHNES) since the 1960s [27]. The most current data available is from 2011 to 2014 and is based on fifteen sampling locations across the United States [27]. The 20,491 participants are across all age ranges and racial/ethnic groups include non-Hispanic white, non-Hispanic black, non-Hispanic Asian, and Hispanic [27]. NHNES also oversamples minority groups in order to obtain the census population rates of these particular groups [27]. The obesity rate for adults is 36% [28]. Women have a higher obesity prevalence than men (38.8% vs. 34.3%) [28]. 
Obesity has been shown to increase a woman’s risk of developing breast cancer. The higher a woman’s BMI and the more weight she carries, the higher her risk of developing breast cancer. Renehan et al. 2008 conducted a meta-analysis of 221 cancer studies of which 34 studies were for breast cancer [29]. The study populations were from North America, Europe, Australia, and Asia-Pacific and contained 31,839 participants (7,930 were premenopausal and 23,909 were postmenopausal) [29]. Their results showed that for a 5kg/m2 increase in BMI, a woman’s relative risk of developing postmenopausal breast cancer is 1.15 (95%CI = 1.08-1.23), 1.09 (95%CI = 1.04-1.14), and 1.31 (95%CI = 1.15-1.48) in the North American, European/Australian, and Asia-Pacific, respectively [29]. 
2.1.1.4	Race and Ethnicity
Different racial and ethnic backgrounds can increase a woman’s risk of developing breast cancer. SEER data collected from 2010 to 2014 on the incidence of breast cancer in the United States population along with the mortality [22]. The overall incidence rate of breast cancer in the United States is 124.9 cases per 100,000 women [22]. White, non-Hispanics, and black women have higher incidence rates (127.7, 130.4, and 125.1 respectively) than the overall incidence rate (124.9) and other minority groups Asian/Pacific Islander (98.5), American Indian/Alaska Native (82.2) and Hispanic (93.1) [22]. However, black women are the most likely to die of breast cancer (29.2 deaths per 100,000 women) compared to any other racial group including white and non-Hispanic women (20.6 and 21.9, respectively) [22]. White women are more likely to be diagnosed with breast cancer than black women, but have a lower mortality rate than black women and the overall rate (21.2) [22]. 
Table 2. Female Breast Cancer Incidence and Death Rates SEER data for 2010-2014, represent the number of new cases of invasive cancer and deaths per year per 100,000 women.










Minorities have higher rates of other risk factors including smoking and obesity which have already been discussed as risk factors for breast cancer. According to the National Center for Health Statistics, the 2011-2014 NHNES survey indicated that Non-Hispanic whites had an obesity rate of 34.5% (consistent with the national rate of 36%), Non-Hispanic blacks had a 48.1% obesity rate, and Hispanics had an obesity rate of 42.5% [28]. Non-Hispanic Asians had a lower obesity rate of 11.7% [28]. There is a higher obesity rate for Non-Hispanic black women compared to black men (56.9% vs. 37.5%) [28]. According to the CDC’s 2015 National Health Interview Survey (NHIS) which interviews randomly selected 33,672 individuals 18 years and older across the United States annually to complete a questionnaire about their health status [30]. This questionnaire includes sex, age, race/ethnicity, education, health insurance coverage, smoking status, and other health questions [30]. The study found that 15.1% of the United States population in 2015 currently smoked cigarettes [30]. Women are less likely to smoke than men are (13.6% vs. 16.7%) [30]. There was also difference in smoking status among different racial and ethnic groups [30]. The highest rate of smoking was in the American Indian/Alaska Native population (21.9%) while the lowest rate of smoking was in the Asian population (7.0%) [30]. Both non-Hispanic black and non-Hispanic white individuals had higher rates of smoking than the national rate (16.7% and 16.6% respectively) [30]. 







Table 4. Smoking racial and ethnic disparities in the United States.	









2.1.1.5	Hormone Replacement Therapy (HRT)
Hormone replacement therapy (HRT) is a treatment for menopausal symptoms such as hot flashes, dyspareunia, atrophic vaginitis, sleep disturbances, and osteoporosis [31]. HRT comes in two forms: estrogen only and combination of estrogen and progesterone. HRT in both forms has been associated with the development of breast cancer in women who have taken HRT in their lifetimes. Thorbjarnardottir et al. 2014 conducted a study on hormone therapy and breast cancer risk on 16,928 Icelandic women 48 years and older from 1979-2006 [32]. The authors found that women who use combined estrogen and progesterone HRT had a higher breast cancer risk than their estrogen only-HRT user counterparts (HR= 2.61; 95%CI=2.00-3.41) vs. (HR=1.13; 95%CI=0.85-1.49) [32]. Ross et al. 2000, analyzed 3,534 women in Los Angeles County, California in the 1987 to 1996 ages 55 to 72 years old for risk of breast cancer due to use of HRT [33]. The authors reported that women who combined HRT were more likely to develop breast cancer than women who only used estrogen-HRT which showed no statistical difference (OR=1.24, 95%CI=1.07-1.45; OR=1.06; 95%CI=0.97-1.15) [33]. How long a woman uses HRT has an effect on her breast cancer risk along with the type of HRT used. Ross et al. 2000 found that the longer women used HRT (greater than 121 months) the more likely they were to develop breast cancer than women who utilized HRT for 61-120 months and 1-60 months (OR=1.79, OR=1.58, and OR=1.19, respectively) [33]. Thorbjarnardottir et al. 2014 saw similar results with their study in the Icelandic population for estrogen progesterone HRT women had a higher risk of developing breast cancer if they had been taking HRT for more than 5 years (OR=2.58; 95%CI=1.88-3.56) vs. taking HRT less than 5 years (OR=1.87; 95%CI=1.32-2.64) [32]. 
2.2	Genetics and Breast cancer
In addition to environmental risk factors, genetic variations play a large role in cancer development. Specifically, cancer develops when specific variants (or mutations) are present in genes that control cellular growth and development functions [34]. When these mutations occur, a normal cell may become unregulated, grow, and/or replicate uncontrollably, which results in a tumor. This abnormal growth is due to the imbalance between cell proliferation and cell death. Regulatory gene mutations usually occur in somatic cells in an individual, and are not inherited. However, some gene mutations occur in germ cells, and may be hereditary. The hereditary type of breast cancer is called Hereditary Breast and Ovarian Cancer Syndrome (HBOC) [34]. 
Epigenetic factors such as DNA methylation and histone modification are thought to play a role in breast cancer development [35]. DNA methylation occurs when a methyl group binds to a cytosine-guanosine (CpG) dinucleotide and tend to cluster in regions known as CpG islands [35]. When heavy methylation occurs in CpG islands (which are common promoter regions for proteins), transcription factors cannot bind to these regions and can effectively silence the gene [35]. Histone modification occurs when acetyl or methyl groups bind to the histones and prevents the histones from opening up during transcription (no mRNA copy is made and no protein is made) [35]. This is another way to silence, or turn off, a gene. In breast cancer, methylation and histone modification occur in estrogen receptors (ERs) [36]. Vo et al. 2012 compiled a review article on epigenetics and breast cancer [36]. The authors found that the women who have a suppressed ER receptor (ER-/methylation) have poorer outcomes than women who still have a functioning ER receptor [36]. 

2.2.1	Family History of Breast Cancer
2.2.1.1	Heritability of Breast Cancer
About 5-10% of all breast cancers are heritable and can be classified as HBOC  ADDIN EN.CITE [37]. The most common breast cancer mutations are located in two Breast Cancer Susceptibility Genes, BRCA1 and BRCA2  ADDIN EN.CITE [37]. A woman’s risk of developing breast cancer increases if she has a first degree relative who has had breast cancer [4]. A first degree relative includes a mother, sister, or daughter. Male breast cancer is rare, but can be found in families with a history of breast cancer. 
The remaining 90-95% of breast cancer cases are the result of de novo mutations in somatic breast tissue cells  ADDIN EN.CITE [4, 34]. These mutations would not be passed down through the generations because they have not occurred in the germline of the person with cancer. 
2.2.2	Common Genetic Mutations in Breast Cancer
2.2.2.1	BRCA1/BRCA2
The most common breast cancer mutations are in the breast cancer susceptibility genes, BRCA1 and BRCA2  ADDIN EN.CITE [37-40]. These genetic variants increase a woman’s risk of developing both breast and/or ovarian cancer  ADDIN EN.CITE [37, 41]. Together, variants in both BRCA1 and BRCA2 account for 20 to 25% of hereditary breast cancers and about 5 to 10% of all breast cancers  ADDIN EN.CITE [42, 43]. Women who have these mutations tend to develop breast cancer at a younger age compared to other breast cancer cases. Frank et al. 2002 analyzed 10,000 individuals of African and European who had or did not have a family history of breast cancer for the three most common BRCA1 and BRCA2 mutations found in individuals with Ashkenazi Jewish ancestry  ADDIN EN.CITE [44]. In individuals who had developed breast cancer after age 50 years had a 2.3% mutation rate (no family history) and 10.2% mutation rate (family history)  ADDIN EN.CITE [44]. In individuals who had developed breast cancer before the age of 40 years had a 13.2% mutation rate (no family history) and 50.7% mutation rate (family history)  ADDIN EN.CITE [44]. SEER data from 1975 to 2012 on the United States population determined the median age of diagnosis for breast cancer in women was 61 years for the general population [4]. 
BRCA1 and BRCA2 can be inherited from one’s mother or father. A person who has a BRCA1 or BRCA2 mutation has a 50% chance of passing on the mutation to each child. Few de novo mutations have been reported for BRCA1 and BRCA2 in the literature. The de novo mutation rate is relatively low at 0.4% and 0.1% for BRCA1 and BRCA2, respectively  ADDIN EN.CITE [45]. This de novo mutation rate may be higher than reported in the literature due to higher BRCA1/BRCA2 genetic testing in families with a history of BRCA1/BRCA2 cancers. The testing is typically performed in women with a family history of breast cancer rather than genetic testing of the entire population. 
The frequency of specific BRCA mutations differs among racial and ethnic populations. Hall et al. 2010 conducted genetic testing for BRCA1/BRCA2 mutations on 46,276 women between 1996 to 2006 in the United States  ADDIN EN.CITE [46]. The women self-identified as African, Ashkenazi Jewish, Asia, Central/Eastern European, Latin American/Caribbean, Native American, Near/Middle Eastern, and Western/Northern European  ADDIN EN.CITE [46]. Based on their results, Hall et al. estimated that deleterious BRCA1/BRAC2 mutation is present in 1 in 400 to 1 in 800 people in the general population  ADDIN EN.CITE [46].  Women of Ashkenazi Jewish decent, however, have a higher risk (1 in 40) of carrying a BRCA1/BRCA2 mutation, which is attributed to three founder mutations  ADDIN EN.CITE [46]. Hall et al. 2010 found that women of African ancestry had a BRCA1/BRCA2 mutation rate of 15.6%, Western European women had 12.1% BRCA1/BRCA2 mutation rate, and Middle Eastern women had 9.4% BRCA1/BRCA2 mutation rate  ADDIN EN.CITE [46]. 
Antoniou et al. 2003 conducted a meta-analysis of 22 studies across the globe involving 8,139 women with breast or ovarian cancer of which 500 were found to have germline mutations in BRCA1/BRCA2  ADDIN EN.CITE [47]. Women with a BRCA1 mutation had a 65% risk of developing breast cancer by the age of 70 years and a 39% of developing ovarian cancer by the same age  ADDIN EN.CITE [47]. Chen et al. 2008 conducted a meta-analysis of 10 studies from various countries with 18,432 families of which had 1,853 carriers of BRCA1 or BRCA2 mutations [48]. Based on their results, women with BRCA1 mutation have a breast cancer risk of 55% and an ovarian cancer risk of 39% [48]. Women with a BRCA2 mutation have a breast cancer risk of 47% and an ovarian cancer risk of 17%.  In comparison, 12% of women in the general population will develop breast cancer over the course of their lifetime and a 1.3% lifetime risk of developing ovarian cancer [4].  
2.2.2.2	Other Genes and Syndromes Associated with Breast Cancer
Variants in several other genes are associated with developing breast cancer and other syndromes. Genes that have been associated with an increased breast cancer risk are ATM, BRIP1, CHEK2, MRE11A, MSH6, NBN, PALB2, PMS2, RAD50, and RAD51C [49]. All of these genes, except CHEK2 which is a tumor suppressor, are involved in the repairing of damaged DNA in the cell [49]. MRE11A, NBN, and RAD50 form the MRN complex that helps to repair damaged DNA [49]. PALB2 localizes with BRCA2 and both combined help to repair damaged DNA [49]. 
In addition to variants that as associate with development of breast cancer only, several syndromes that manifest increased risk of breast cancer, including Li-Fraumeni syndrome, Cowden syndrome, diffuse gastric and lobular breast cancer syndrome, and Peutz-Jeghers syndrome [19]. These syndromes are also associated with autosomal dominant transmission and high penetrance, similar to HBOC. 
Li-Fraumeni syndrome, also known as Sarcoma, Breast, Leukemia and Adrenal Gland (SBLA) syndrome, is a cancer predisposition syndrome associated with the development of many types of cancers including, but not limited to soft tissue carcinomas, pre-menopausal breast cancer, brain tumors, and leukemia [50]. About 70% of Li-Fraumeni syndrome cases are caused by a germline pathogenic TP53 mutation and 80% of families with features of Li-Fraumeni syndrome have a TP53 mutation [50]. Women with Li-Fraumeni syndrome are at an increased risk of developing breast cancer, with the median age of cancer diagnosis at age 33 years [50]. 
Cowden Syndrome is part of the PTEN Harmatoma Tumor Syndrome (PHTS) and puts individuals at risk for developing benign and malignant tumors in the thyroid, breast, and endometrium [51]. The overall lifetime risk of these women of developing breast cancer is 85% which manifests between 38 and 46 years [51]. About 90% of individuals with a PTEN pathogenic mutation manifest symptoms, such as cancer, by late 20s [51]. 
Hereditary diffuse gastric cancer (HDGC) is associated with germline mutations in CDH1 [19]. HDGC is an autosomal dominant syndrome and is associated with developing both gastric and lobular breast cancer [19]. Lobular breast cancer occurs in about 10% to 15% of breast cancer cases [19]. However, women with a CDH1 mutation have a 30% to 50% lifetime risk of developing lobular breast cancer [19]. About 25% of families with HDGC have a pathogenic CDH1 mutation[19]. 
Peutz-Jeghers syndrome (PJS) is an autosomal dominant condition associated with gastrointestinal polyposis, mucocutaneous pigmentation, and cancer predisposition [52]. These cancers include colorectal, gastric, pancreatic, ovarian and breast cancer [52]. STK11 is an autosomal dominant mutation for PJS with 100% penetrance [52]. About 94% to 96% of individuals with PJS have a pathogenic STK11 mutation [52]. The lifetime risk of breast cancer development in women with PJS is 32% to 54%, with the average age of diagnosis ranging from 37 to 59 years [52]. 
3.0 	breast cancer screening
Roth et al. 2011 utilized data from the United States 2003 National Health Interview Survey (NHIS) of 361 breast cancer survivors diagnosed with breast cancer between 1980 and 2003 to determine how their breast cancer was found  ADDIN EN.CITE [53]. Most women (57%) reported discovering their breast cancer through a clinical breast examination or after reporting breast abnormalities to their primary care physician  ADDIN EN.CITE [53]. Roth et al. 2011 also reported that 43% of the breast cancers were detected by mammography  ADDIN EN.CITE [53]. Some women do not utilize self-examinations or do not notice any abnormalities in their breasts. In these situations, breast cancer screening is an effective method for detecting breast cancer. Screening is defined as looking for cancer before a person has any symptoms [54]. 
There are several methods used to detect breast cancer are self-examinations, clinical breast exams, magnetic resonance imaging (MRI), and mammograms [54]. 
3.1	self-examination and clinical breast exams
A breast self-examination can be done by a woman on her own breasts. This is not widely used or strongly recommended by physicians due to the lack of training the average person has. The USPSTF does not have a recommendation due to lack of research and evidence  ADDIN EN.CITE [55, 56]. Several organizations including the American Cancer Society and the Canadian Cancer Society recommend all women over the age of 20 years perform regular self-breast examinations [56]. The appeal of using a self-examination is the ability to perform the exam at one’s convenience and privacy. Breast self-examinations have a lower sensitivity (26%) compared to mammography or clinical breast examination [57]. Specificity is also lower ranging from 66% to 81% when compared to mammography and clinical breast examinations [57]. A study has shown that sensitivity can be increased with proper training for how to perform a self-examination, but the false positives also increased [57]. As the false positives increase, the burden on the health care system increases. Every false positive must be followed up in the clinic by a clinical breast examination and a mammogram [56]. This leads to an added expense on the health care system including use of resources, doctors, nurses, and other trained staff in order to perform this follow up care [56]. It also causes the patient added stress and anxiety along with additional exposure to radiation that could potentially increase breast cancer over time [56]. 
A clinical breast exam is typically performed before a mammography, at an annual physical, or after a mammography as follow up for abnormal results [58]. A trained physician, nurse, or technician can perform the examination. A clinical breast exam is crucial for diagnosis and surveillance of benign and malignant breast cancer [58]. A clinical breast exam is recommendations vary for women at average risk of developing breast cancer [59]. According to a 2016 review of clinical trials evaluating mammography and clinical breast examination, clinical breast examination has a sensitivity of 54% and specificity of 94% [59]. 
A visual inspection of the breasts is first performed to observe any unusual changes in the breasts appearance. This includes changes in size, shape, symmetry, nipple size, texture, and color [58]. The patient is asked to sit upright and may be asked to raise and lower their arms to further observe changes [58]. Any changes that are noted in the breast tissue are recorded in the medical record [58].
The second phase of a clinical breast examination is palpation, or the process of using one’s hands to examine the breast tissue. The MammaCare technique developed by the MammaCare Foundation in 1974 is the standard for performing and teaching clinical breast examinations [60]. The patient lies down and places one hand above their head which helps to flatten out the breast tissue [58]. The approach teaches palpation using a vertical strip pattern (also known as “wagon wheel” or “spoke” method) with circular motions made with the pads of the middle three fingers in a cupped position using different pressures  ADDIN EN.CITE [58-60]. The three pressures are light, medium, and deep and are helpful in detecting lumps at different depths in the breasts  ADDIN EN.CITE [58-60]. Overall consistency of the breast is documented along with any masses or tender lesions detected [58]. The patient’s medical record should contain any abnormalities including size, shape, texture, mobility, delimitation, tenderness, and depth [58]. The examiner also palpates the nipple for any abnormalities including discharge and texture [58]. 
3.2	mammography
Mammography is the most common screening test for breast cancer with 64% of 40 years and older women having received a mammogram in the past two years [13, 54]. A mammogram is an X-ray of the breast and a tumor is found when a white mass appears on the X-ray [54]. Mammograms are less effective in women under the age of 50 due to dense breast tissue [54]. The denser breast tissue is, the whiter it appears on a mammogram. Since tumors are detected through white spots on a mammogram, it can be hard to distinguish between normal tissue and a tumor in younger women with dense breasts. 
Recommendations for mammography vary depending on which organization is referred to.  Most recommendations depend on a woman’s age, family history, and breast density. Most organizations including the American College of Obstetricians and Gynecologists, the American Cancer Society, and the International Agency for Research on Cancer recommend annual screening from ages 50-74 years of age [61]. The U.S. Preventive Services Task Force, the American College of Physicians, and the American Academy of Family Physicians recommend biennial screening from ages 50-74 [61]. All of these organizations recommend that women with an average risk of breast cancer ages 40 to 49 should at least have the option of receiving screening, especially clinical and self-examinations [61]. 
Mammograms are used for both screening and diagnostic purposes. A screening mammography is routine and done on healthy women to check for abnormalities in the breast tissue. Physicians also encourage women at higher risk for breast cancer due to family history to be screened more frequently. Diagnostic mammography is used for women who are experiencing symptoms or for follow-up visits after an abnormal screening result is obtained. 
3.3	rates of breast cancer screening
The American Cancer Society’s 2015 guidelines have a varied recommended age to begin an annual mammogram varies depending on family history, breast density, and personal history of breast biopsy, but most individuals generally start at age 40 years old  ADDIN EN.CITE [62, 63]. However, many women do not undergo screening due to various reasons including lack of insurance, time, or access to facilities [64].  According to the Centers for Disease Control (CDC), in 2015 only 64.0% of women in the general population in the United States over the age of 40 years old received a mammogram while 67.2% of women over the age of 50 years old received a mammogram [13]. Overall, among women with health insurance, 69.7% utilized mammography: 72.2% of women with private insurance received a mammogram versus 57.7% of women with Medicaid. These proportions are still higher than those for uninsured women, of whom only 30% receive an annual mammogram. [13]
3.4	Health disparities in breast cancer screening
Breast cancer screening varies by race and ethnicity. Caucasian women are more likely to develop breast cancer, but also more likely to receive an annual mammogram than black or Hispanic women  ADDIN EN.CITE [16, 65, 66]. A 2016 study by DeSantis et al. based on data from the National Cancer Institute, CDC, and the North American Association of Central Cancer Registries on the general population in America reported that 11.1% of African American women developed breast cancer in their lifetime whereas 13.1% of Non-Hispanic White women did  ADDIN EN.CITE [16]. Goel and colleagues analyzed data on mammogram usage alone and other preventative care measures from the 1998 National Health Interview Survey (NHIS) of women ages 50 to 74 years old across the United States [65]. Their results showed that Blacks were more likely than Whites to receive breast cancer screening (88% vs. 86%) while Hispanics and Asian-Americans and Pacific Islanders were less likely to receive breast cancer screening in the form of a mammogram than their White or Black counterparts (77% and 71% versus 88% and 86%, respectively) [65]. A 2007 meta-analysis assessed results from studies of cancer screening in the United States population published in PubMed from 1997 to 2007 [66]. This analysis reported that Hispanics are less likely to receive mammogram screening than non-Hispanic whites due to their socioeconomic status, education, and lack of health care knowledge [66]. 
According to the CDC’s data on the United States’ general population of women over the age of 40 years, in 2015 65.3% of Caucasian women, 69.8% of African American women, 51.5% of American Indian or Alaska Native women, 59.7% of Asian women, and 62.7% of women with more than one racial background received an annual mammogram [13]. Similar to results from the meta-analyses, only 50.3% of Hispanic women age 40 years and older received a mammogram, although 71.6% of Hispanic women age 50 years and older received a mammogram [13].
3.5	genetic testing for breast cancer genes
3.5.1	BRCA1/BRCA2
As described above, breast cancer is usually identified by a standard physical examination or mammogram, whereas genetic mutations are detected via several different tests. BRCA1 and BRCA2 genetic mutations have numerous variants including pathogenic, benign, and variants of unknown significance (VUS). A VUS is a mutation in a gene that has limited or conflicting evidence about whether the mutation is associated with an increased risk of developing a disease, in this case breast cancer. Many VUS’s exist in many genes including BRCA1 and BRCA2. ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), a genetic database for known genetic mutations, was searched on March 2, 2018 for BRCA1 and BRCA2 mutations [67]. Of the 6,574 results for BRCA1, 2,366 had a result of uncertain significance, or VUS, while BRCA2 had 9,099 results and 4,057 were of uncertain significance. According to Ready et al. 2011 had a connection with Myriad Genetic Laboratories who reported that 7% of individuals who underwent BRCA1 and BRCA2 testing had a VUS, 5-6% of European ancestry individuals had a VUS, and 21% of individuals with African ancestry had a VUS [68]. 
To qualify for BRCA1 and BRCA2 genetic testing, individuals have to meet specific criteria. According to the National Comprehensive Cancer Network (NCCN) 2017 guidelines, the two primary qualifications for genetic testing are an individual from a family with a known deleterious BRCA1/BRCA2 gene mutation or personal history of breast cancer with an additional qualification, such as diagnosis ≤ 45 years of age  ADDIN EN.CITE [69]. These additional qualification guidelines are listed in Table 5.


Table 5. NCCN Additional 2017 Guidelines for BRCA1/BRCA2 Testing.	
NCCN Additional 2017 Guidelines for BRCA1/BRAC2 Testing	Subcategory Requirements
Diagnosis ≤ 45 years	
Diagnosis ≤ 50 years with	An additional breast cancer primary≥ 1 close blood relative with breast cancer at any age≥ 1 close relative with pancreatic cancer≥ 1 relative with prostate cancer (Gleason score ≥7)An unknown or limited family history
Diagnosis ≤ 60 years with	Triple negative breast cancer
Diagnosis at any age with	≥ 2 close blood relatives with breast cancer, pancreatic cancer, or prostate cancer (Gleason score ≥7) at any age≥ 1 close blood relative with breast cancer diagnosed ≤ 50 years≥1 close blood relative with ovarian carcinomaA close male blood relative with breast cancerFor an individual of ethnicity associated with higher mutation frequency (eg, Ashkenazi Jewish) no additional family history may be required
Personal history of ovarian cancer	
Personal history of male breast cancer	
Personal history of prostate cancer with family history	
Personal history of prostate cancer with family history	
BRCA1/BRCA2 mutation detected by tumor profiling in the absence of germline mutation analysis	
First or second degree blood relative meeting any of the above criteria	
Third-degree relative who has breast/ovarian cancer with	≥ 2 close blood relatives ≤ 50 yearsOvarian cancer 
 ADDIN EN.CITE [69]
Once an individual has met the criteria, she (or he) may proceed with BRCA1 and BRCA2 genetic testing. Several commercial companies provide genetic testing specifically for BRCA1 and BRCA2, including Myriad Genetic Laboratories, Ambry Genetics, and GeneDx. Many insurance companies will cover the cost of genetic testing and genetic counseling sessions if individuals meet the testing criteria, especially because the cost has come down in recent years [70].  The standard process a patient undergoes for genetic testing involves a referral to a genetic counselor, a pre-counseling session, ordering of the test, and post-counseling session [70]. A pre-counseling genetic counseling session involves a discussion of a patient’s concerns, explanation of genetic terms, and consent to the genetic test [70]. The post-counseling genetic counseling session involves explanation of test results and the next steps for the patient [70]. 
3.5.2	Gene Panels
Gene panels have been developed as the costs of genetic testing have decreased. Traditional genetic testing assesses mutations within a specific gene, whereas gene panels test several genes simultaneously  ADDIN EN.CITE [71, 72]. These panels are useful when a family history is not known or a family mutation for BRCA or another breast cancer related gene is unknown. The tests are also useful to determine the course of treatment, which is dependent on the mutation present. 
	Doherty et al. 2013 conducted a retrospective review on gene panel testing versus traditional BRCA1/BRCA2 testing. The genetic counselor offered a six gene panel instead of the BRCA1/BRCA2 test to clients meeting the BRCA1/BRCA2 testing criteria., The cost-effectiveness of a 6-gene panel was analyzed for BRCA1/BRCA2, TP53, PTEN, STK11, and CHD1 compared to traditional BRCA1/BRCA2 testing [71]. A traditional BRCA1/BRCA2 test is about $2,200 compared to the 6-gene panel given at $3,300 [71]. A traditional test of six genes, separately, would have cost $6,600 compared to the 6-gene panel test ($3,300). In most cases, a gene panel test is more beneficial and cost-effective to run a gene panel test than a single gene test, especially when doctors and genetic counselors are unsure of what gene may be causing the phenotype. However, if a clinician is certain that a patient has a specific BRCA mutation due to family history and other relatives with a BRCA mutation, the traditional BRCA1/BRCA2 genetic test is more efficient  ADDIN EN.CITE [71, 72]. 
	One drawback of gene panels is the increased likelihood of identifying a mutation of unknown significance[58]. This result may cause a patient anxiety and unnecessary stress of not knowing the exact risk factors associated with a particular mutation. 
3.6	medicaid coverage and the affordable care act
3.6.1	Overview of the Affordable Care Act 
The Patient Protection and Affordable Care Act of 2010 (ACA) [P.L. 111-148] was enacted on March 23, 2010 in the United States and was upheld by the Supreme Court on June 28, 2012 [73, 74]. The main overarching goal of the act is to make healthcare more affordable and accessible to everyone in the country. According to the U.S. Census Bureau in 2010, 49.9 million Americans did not have insurance coverage [75]. In 2016 the U.S. Census Bureau estimated that 28.1 million Americans did not have insurance coverage [76]. 
The main changes that ACA enacted were consumer protections, improvements to quality of care and lowering costs, and increasing affordable care [77]. Some of the consumer protections introduced were prohibition of denying coverage based on pre-existing conditions, elimination of lifetime limits on insurance coverage, and appealing insurance company decisions [73, 77]. Quality of care and lowering costs of health care included providing small businesses with health insurance tax credits, free preventative care (including mammograms and colonoscopies), and the Prevention and Public Health Fund [73, 77]. The ACA also included steps to increase affordable care including extending coverage for young adults which allows them to stay on their parents insurance until the age of 26 years old and the Medicaid expansion option on a state basis to more low income individuals [73, 77]. All health plans under ACA must contain the ten essential benefits package in order to be offered in the marketplace. These include ambulatory patient services, emergency services, hospitalization, pregnancy, maternity & newborn care, mental health & substance use disorder services including behavioral health treatment, prescription drugs, rehabilitative and habilitative services & devices, laboratory services, preventive & wellness services & chronic disease management, and pediatric services including oral and vision care (not covered for adults) [78]. 
The ACA was amended on December 13, 2016 through the 2018 Tax Reform Bill known formally as P.L. 114-255 that was passed through both the House of Representatives and the Senate [74]. The largest change includes the removal of the individual mandate which requires everyone to have health insurance otherwise they face a large penalty [74]. The effects of this amendment are not yet known, but economists and health care professionals speculate that the number of uninsured Americans will increase. 
This amendment of the ACA does not apply to the Medicaid study done at the managed care organization in this study because the data was collected and analyzed before the amendment was passed. The legislative changes will affect future analyses and conclusions obtained on this population. 
3.6.2	Differences between Medicaid and Medicare 
Medicaid is a joint federal and state program that provides health coverage in the United States [79]. Medicaid serves certain mandated eligible groups of people including low income families, individuals with disabilities, and pregnant women [79]. Each state manages their own Medicaid program and in order to participate in this program and receive federal funding, these mandated eligible groups must be served [79]. In 2010 ACA allowed states to expand their Medicaid programs to cover individuals with income levels at or below 133% poverty level [74, 77, 79]. 
Medicare is a federal government program for individuals with a disability or over the age of 65 years [80] and has four different parts: Part A, Part B, Part C, and Part D [81]. Part A provides inpatient hospital care, inpatient stays in skilled nursing facilities, and hospice and home health services [81]. Part B offers doctor & clinical lab services, outpatient & preventive care, home health care, screenings, surgical fees & supplies, and physical & occupational therapy [81]. Part C combines Part A and B into one program called Medicare Advantage which streamlines service for beneficiaries [81]. Finally, Part D provides help to cover the cost of prescription drugs and helps to lower additional costs for them in the future [81]. Plan D may be a stand-alone plan or included in addition to Parts A and B or Part C [81]. 
3.6.3	Breast Cancer Screening Coverage Before and After the Affordable Care Act
Prior to the ACA, preventative care for screening mammograms and colonoscopies typically required a deductible, copay, or coinsurance [73]. This requirement created an increase cost burden for patients and also deterred people who had insurance from receiving screening. With the passage of ACA, Medicaid and Medicare follow the USPSTF recommendations, that is, annual mammogram screening ages 50 to 74 years [82]. In 2010 preventative care no longer required a deductible, copay, or coinsurance, essentially making the services free for individuals with insurance  ADDIN EN.CITE [74, 77, 83]. 
	In 2018, Sun et al. used SEER data from 2013 to 2014 to analyze breast cancer screening rates before and after the ACA implementation; they reported significant increase in the incidence rate ratios (IRRs) for early-stage breast cancer diagnosis before and after the implementation of ACA (55; 95%CI=54.6-56.3 vs. 56.9; 95%CI =56.0-57.7 cases per 100,000 person-years) [84]. In addition, they reported a significant difference in the relative difference in IRRs (DID) for early vs locally advanced, metastatic stages of breast cancer incidence (DID, 1.050; 95%CI =1.006-1.098; p = 0.03) [84]. These results indicate that women are utilizing screening because more cases are being detected at earlier stages after ACA than before ACA. A 2015 study in California on Medicare beneficiaries aged 65 years and above reported that the decline in mammogram screening was slowed after the implementation of the ACA compared to before the ACA  ADDIN EN.CITE [85], most likely due to the $20 co-pay elimination for beneficiaries  ADDIN EN.CITE [85]. 
4.0 	Managed care organization breast cancer screening: Goal
As described earlier, increased breast cancer screening leads to earlier and increased identification of early stage breast cancer that is more treatable. Since these earlier stages are easier to treat, the cost of treatment is also lower. Breast cancer screening such as mammography is beneficial not only to patients, but to healthcare and insurance providers. The 2010 Patient Protection and Affordable Care Act (ACA) mandated that Medicare and Medicaid providers establish preventive breast and colon cancer screening programs for their clients (with no co-pays).  However, almost 50% of women do not receive an annual mammogram  ADDIN EN.CITE [83, 85]. Thus, although the cost of screening has been eliminated, barriers to screening still exist. 
The overall goal of the current study is to assess the mammogram screening trends among our managed care population (who receive Medicaid).  Specifically, I want to determine 
(1) baseline characteristics of our Medicaid population, e.g., age, race, ethnicity, regional distribution, health risk factors, family history of breast cancer, obesity, smoking prevalence, and variables representing health care usage.
(2) which characteristics differ between women who undergo screening versus women who are not screened.
(3) whether results in our managed care population are similar to results from other populations

	Results from this study will inform longer-term management decisions to develop interventions to address disparities and thus increase the rate of mammogram screenings in this population. For example, if racial minorities are less likely to receive a regular mammogram than Caucasian women the MCO can develop outreach programs designed for these women. Or if women who obtain few mammograms reside in certain regions in Pennsylvania, the MCO can determine if there is a lack of resources in those areas.  Also, if younger women are less likely to get a mammogram, the MCO may target interventions to improve communication between patients and their primary care physicians.
Finally, the majority of the literature on breast cancer screening, and possible barriers to screening, is based on studies of fee-for-service care.  Limited information is available on screening rates, and possible barriers, among managed care organizations.   Our results will contribute to this field. 
4.1	Materials and Methods
4.1.1	Population
The sample included 6,922 women of eligible screening age (52 to 74 years old) who are currently members at the managed care organization. Although the American Cancer Society’s 2015 guidelines recommend that all women ages 45 to 54 years should get a mammogram every year which women ages 40 to 44 years having a choice to start annual mammogram screenings [86], the managed care organization follows the Healthcare Effectiveness Data and Information Set (HEDIS guidelines). Thus, for this study, the 2017 inclusion criteria for breast cancer screening were followed to determine the dataset [87]. These criteria included women ages 52 to 74 years old as of December 31, 2016. In addition, to be included in the study, women must have had continuous health care coverage as of October 1 two years prior to the measurement year through December 31st of the measurement year. In other words, women must have had continuous coverage from October 1, 2014 to December 31, 2016, but women who had a gap in continuous coverage of up to 45 days in each full calendar year were also included. I also excluded women who had a bilateral, unilateral, or two unilateral mastectomies within fourteen days of each other. 
Several variables were chosen for the dataset including age, race, ethnicity, county residence, Pennsylvania region, number of health conditions, total number of primary care physician (PCP) visits, inpatient admissions, and number of Emergency Department (ED) visits. Geographic location was included (rural and urban counties) along with regional information in Pennsylvania to determine if any environmental factors such as, lack of resources or facilities, which were contributing to low mammogram screening frequencies. Family history for each woman was also included because a woman with a family history of breast cancer should be receiving mammograms more often than a woman with no family history. Smoking status and obesity status are known risk factors for breast cancer and were also included in the analysis.












































Table 7. Categorization of individual health conditions into various categories according to what system the condition affects.	

	Condition Categories	Individual Conditions
1.	Heart	Congestive heart failure (CHF), coronary artery disease (CAD), hyperlipidemia, hypertension (HTN), atrial fibrillation, CHF additional, cardiomyopathy, diastolic dysfunction, cardiogenic shock, valvular heart disease, syncope, cerebro-vascular disease
2.	Nervous System	Central nervous system disease, cerebral palsy, epilepsy, migraine, multiple sclerosis, muscular dystrophy, paralysis, Parkinson’s Disease, (spinal cord injury) SCI, Spina bifida, spina bifida SCI, seizure stratified, angina
3.	Lung	Asthma, cystic fibrosis, Tuberculosis, chronic obstructive pulmonary disease (COPD)
4.	Autoimmune Diseases	Rheumatoid arthritis, Lupus connective tissue disorders, immune deficiency, myasthenia gravis
5.	Surgical Procedures	Transplant, defibrillator, prosthetic valve
6.	Conditions Treated	Acid Related Disorders, Dementia, Glaucoma, Gout Hyperuricemia, Morbid obesity (MO), Pain, Psychological Disorders, Psychoses, Thyroid Disorders
7.	Digestive System	Chronic hepatitis, inflammatory bowel disease, liver disease, pancreatitis chronic
8.	Systemic (Blood)	Coagulation defects, Hematological Sickle Cell, hemo stratified (abnormal platelet count), edema, stroke, anemia, Type 1 Diabetes, Type 2 Diabetes, HIV
9.	Kidney	ESRD, renal disease
10.	Bone, Cartilage, Other 	Osteoarthritis, osteoporosis, fall risk, neoplasma malignant

4.1.2	Andersen Health Care Utilization Model
The Andersen Health Care Utilization Model is a conceptual model developed by Ronald Andersen to help understand the factors influencing a person’s usage of health care services [88]. 
The Andersen Model is used to determine the importance of the different variables and how these variables affect why some people use health care services and others do not [88]. For the managed care organization, the model was used to help determine variables that are affecting the usage of mammograms such as age, race, ethnicity, region, and health conditions. According to this model, the usage of health care services are determined by three factors: predisposing factors, enabling factors, and need-related factors [88]. Predisposing factors are the general characteristics that a person has such as age, race, and health beliefs [88]. The predisposing factors in our study are age, race, ethnicity, and family history of breast cancer. Enabling factors are factors that not a trait of the person, but the environment around them [88]. In our study, the enabling factors are the environment in which a woman lives in such as a rurality and region. The need-related factors include a person’s perceived and actual need for health care services [88]. The need-related factors include the number of health conditions a woman has, obesity status, and smoking status of the woman. An additional category was included for the analysis (health care utilization) including number of PCP visits, inpatient admissions, and number of ED visits for each woman. 
4.1.3	Analysis Methods
The statistical program SAS Enterprise Guide 6.1 was used for the analysis. Basic descriptive statistics were calculated to obtain the overall mean, standard deviation, and percentages of breast cancer screening usage and non-usage, age, race, ethnicity, county description, region, over 50 health conditions (see Table 1), family history of breast cancer, obesity and smoking status and total number of health conditions, primary care physician (PCP) visits, specialist visits, inpatient admissions, Emergency Department (ED) visits, and avoidable ED visits (Lane ED) visits. The total number of health conditions did not include obesity because obesity was analyzed as a separate variable. Region (Northwest, Southwest, and Lehigh) was determined via the Pennsylvania Visitors Network website using their Region Map [89]. See Tables 1 and 2 for the breakdown of rural and urban counties along with region which was also determined using The Center for Rural Pennsylvania’s chart [90]. The racial groups of American Indian/Alaskan, Asian/Pacific Islander, and Hawaiian/Pacific Islander were combined into one category of Asian/Pacific Islander due to small sample size from all three groups. Other/System Default and Not Provided groups were combined into one labeled group for the fourth racial group. 
For categorical variables, I assessed whether differences in the frequencies among mammogram users versus non-mammogram users groups were significantly different using a Chi-Squared analysis (proc freq/exact chisq) and a p-value less than <0.05. (Table 1). Fisher’s Exact Test was used to test for differences between mammogram users and non-users for Cystic Fibrosis, Hematological Sickle Cell, Myasthenia Gravis, Spina Bifida, and Tuberculosis due to small sample size. For quantitative variables, I used a t-test (proc glm) to compare the calculated means for mammogram and non-mammogram groups for age, number of health conditions, number of ED visits, number of Lane ED visits, number of PCP visits, number of specialist visits, and number of inpatient admissions.
Prior to performing logistic regression analyses that incorporated multiple variables into the model, I performed a linear regression (proc reg) on the variables to test for collinearity by assessing the tolerance and variance inflation factor (VIF) statistics. Any VIF value larger than five was considered highly correlated with other variables, however, I observed no evidence for extensive collinearity among the variables (Supplemental Table 13).
Next, multiple logistic regression analyses (proc logistic) were performed using mammogram status as the outcome variable using the other variables listed in Table 8 as predictive variables. Age was analyzed as a categorical variable, using the age brackets designated in Table 8. Health conditions were also analyzed as a categorical variable in groups instead of as a continuous variable. The sixty-four health conditions that were reported in the dataset were assigned to different categories based on the organ system the condition affected. See Table 7 for a complete list of health conditions that were analyzed and how they were different categorized. 
Several models were executed before the final, best model was determined (Table 9). For each model, the reference group was women who utilized breast cancer screening with the categorical age as the predictor variable. The first logistic regression only controlled for the predisposing factors including race, ethnicity, and family history of breast cancer. The second logistic regression included the predisposing factors and enabling factors (i.e. county classification as rural or urban and the region in which a woman lived). The third model analyzed the predisposing factors, enabling factors, and the need-related factors (i.e. total number of categorized health conditions, obesity status, and smoking status). The final logistic regression model included the predisposing, enabling, and need-related factors in addition to health care utilization variables (i.e. number of PCP visits, number of inpatient admissions, and number of ED visits). 
The final logistic regression model results are shown in Table 9. The model listed was selected based on the results of an Omnibus Test of Model Coefficient which indicated that the model improved with additional variables and the categorization of the health conditions.
4.2	Results
4.2.1	Population Characteristics
More women were mammogram users versus were non-mammogram users, 0.524 vs 0.477, respectively (Table 8), and the mean age of the women was 59 years old among users and non-users. Breast cancer screening did not differ by age categories (p=0.1681). The majority of the women were Caucasian (69%) with 20% being African American, 2% Asian, and 10% Other. Breast cancer screening differed significantly (p <0.0001) by race; approximately 50% of whites and African Americans were screened, but Asian women had lower levels of screening (45%) and the “Other” category had higher levels (68%). The majority of the women were Non-Hispanic, but Hispanic women were more likely to utilize breast cancer screening versus non-Hispanic women, 0.682 vs. 0.501, respectively (p <0.0001). Women living in the Lehigh valley region were more likely to be screened than women living in the northwest or southwest, 0.623, 0.540, and 0.508, respectively (p< 0.0001). The majority of the women (95%) had no family history of breast cancer, however, women with a family history of breast cancer (0.883) were more likely to receive breast cancer screening than women who had no family history (p<0.0001).
Overall, 77% of women lived in urban counties; but, their frequency of screening was similar between rural and urban counties (p=0.28). Eighty percent of women lived in the Southwest region in Pennsylvania, 11% lived in the Lehigh region, and 8% lived in the Northwest region.
On average, each woman had 4.30 health conditions, but women who utilized breast cancer screening had a significantly higher number of conditions than non-utilizers (4.58 vs. 4.00, respectively p<0.0001). Furthermore, when the number of health conditions per person were categorized into four groups, the proportion of women within each category varied by screening status (Table 7). Finally, each of the sixty-four health conditions were analyzed separately within regards to breast cancer screening status. (Supplemental Table 12)
Family history of breast cancer, obesity and smoking status were also compared between mammogram users and non-users. Mammogram users were significantly more likely to have a family history of breast cancer, be obese, or smoke than non-mammogram users (Table 8). 




Table 8. Descriptive Characteristics of Women 52-74 years old from a PA Managed Care Organization by Breast Cancer Screening Use (n=6,922).	

Variables	All52-74 Years (6,922)	Mammogram Users(3,624)	Non-Mammogram Users(3,298)	p-value
Socio-demographic				
Age  Mean (±SD)	59.09 (3.93)	59.17 (3.93)	59.00 (3.94)	0.0812
Age Group				
    52 – 58 	3,326	1713 (0.515)	1613 (0.485)	0.1440
    59 – 64 	2,977	1566 (0.526)	1411 (0.474)	
    65 – 74 	619	345 (0.557)	274 (0.443)	
Race (frequency)				
    White	4769	2431(0.510)	2338 (0.490)	<0.0001*
    African American	1350	678 (0.502)	672 (0.498)	
    Asian/Hawaiian/American                           Indian/Pacific Islander	137	62 (0.453)	75 (0.547)	
    Others	666	453 (0.680)	213 (0.320)	
Ethnicity (frequency)				
    Hispanic	843	577 (0.682)	266 (0.316)	<0.0001*
    Non-Hispanic	6079	3047 (0.501)	3032 (0.499)	
Rural/Urban (frequency)				
    Rural	1582	847 (0.535)	735 (0.465)	0.2826
    Urban	5340	2777 (0.520)	2563 (0.480)	
Region (frequency)				
    Northwest	574	310 (0.540)	264 (0.460)	<0.0001*
    Southwest	5561	2824 (0.508)	2737 (0.492)	
    Leigh	787	490 (0.623)	297 (0.377)	
				
Health Risk Factors				
Number of Health Conditions Mean (±SD)	4.30 (1.89)	4.58 (1.73)	4.00 (2.00)	<0.0001*
    0 	290	51 (0.176)	239 (0.824)	<0.0001*
    1 – 2 	1905	898 (0.471)	1007 (0.529)	
    3 – 5  	2709	1484 (0.548)	1225 (0.452)	
    6+	2018	1191 (0.590)	827 (0.410)	
Family History of Breast Cancer (frequency)				
    Yes	342	302 (0.883)	40 (0.117)	<0.0001*
    No	6580	3322 (0.505)	3258 (0.495)	
Obesity Status				
    Yes	690	413 (0.599)	277 (0.401)	<0.0001*







Variables	All52-74 Years (6,922)	Mammogram Users(3,624)	Non-Mammogram Users(3,298)	p-value
Smoking Status (frequency)				
    Yes	1036 	599 (0.578)	437 (0.422)	0.0001*
    No	5886	3025 (0.514)	2861(0.486)	
				
Health Care Utilization				
Number of ED visits				
    Mean (±SD)	1.19 (2.17)	1.20 (2.21)	1.17 (2.12)	0.5882
Lane ED				
    Mean (±SD)	0.30 (0.78)	0.31 (0.82)	0.29 (0.74)	0.1967
Number of PCP Visits				
    Mean (±SD)	6.12 (6.17)	7.41 (6.54)	4.70 (5.40)	<0.0001*
Number of Specialist Visits				
    Mean (±SD)	2.33 (1.93)	2.81 (2.00)	1.81 (1.69)	<0.0001*
Inpatient Admissions				
    Mean (±SD)	0.22 (0.72)	0.19 (0.65)	0.26 (0.79)	<0.0001*
*Significant at p<0.05
4.2.2	Logistic Regressions
After assessing differences between mammogram users and non-users for all of the predisposing factors, enabling factors, and need-related factors, separately (Table 8), I performed multivariable logistic regression analyses. 
	First, I used an omnibus test to evaluate which of the following four models best described the data on usage of breast cancer screening: Model 1: predisposing factors (including race, ethnicity, and family history of breast cancer); Model 2: predisposing factors + enabling factors (i.e. county classification as rural or urban and region in which a woman lived); Model 3: predisposing factors + enabling factors + need-related factors (i.e. total number of categorized health conditions, obesity status, and smoking status); and Model 4: predisposing factors + enabling factors + need-related factors + health care utilization variables (i.e. number of PCP visits, number of inpatient admissions, number of specialist visits, number of ER visits, and number of avoidable ER visits). The omnibus test statistics indicated that Model 4 best described the data (Table 9). Thus, socio-demographic factors (that is predisposing and enabling factors), plus need-related factors, and health care utilization variables were all required to predict mammogram users vs. non-users. 

Table 9. Omnibus test results for different logistic regression models comparing mammogram users vs. non-users. 
Model	Factors	df	Chi-Square	p-value
1	Predisposing 	5	2.95	0.7076
2	Predisposing + enabling 	7	6.52	0.4802
3	Predisposing + enabling + need-related 	8	9.73	0.2842
4	Predisposing + enabling + need-related + health care utilization	8	51.46	<0.0001

With a few exceptions, results of the multivariable logistic regression analyses for Model 4 (Table 10) were generally similar to the results of the factors analyzed separately (Table 8). Specifically, breast cancer screening rates did not differ within different age groups. Furthermore, African American women were more likely to receive breast cancer screening compared to Caucasian women (OR=1.28, CI [1.12-1.47], p <0.0001; whereas Hispanic women were almost twice as likely to be mammogram-users versus their Non-Hispanic counterparts (OR=1.88, CI [1.51-2.35], p<0.0001). Women who were organized in the Other classification group (Asian, Hawaiian, Native American, Pacific Islander, and women who did not fit the other racial groups or did not disclose their racial identity) also had an increased likelihood of breast cancer screening compared to Caucasian women (OR=1.30, CI [1.05-1.61], p<0.0001).
Differences in screening were also observed between rural and urban residents, as well as geographic region. Women who lived in rural regions were less likely to receive breast cancer screening than women who lived in urban regions of Pennsylvania (OR=0.77, CI [0.68-0.88], p<0.0001). This result differed from analyses of rural versus urban separately. Furthermore, women who lived in the Southwest region of Pennsylvania were less likely to receive a mammogram than women living in the capital region of the Lehigh valley (OR=0.73, CI [0.61-0.87], p=0.0006). Although women who lived in the Northwest region of Pennsylvania also had lower levels of screening than those in the Lehigh valley, this difference was not significant.  
Women who had zero health conditions were significantly less likely to receive breast cancer screening than women who had six or more health conditions (OR=0.30, CI [0.21-0.42], p<0.0001); however, screening rates did not differ amongst women who had between one and two conditions and three to five health conditions compared to women with six or more health conditions. Women who had a family history of breast cancer were dramatically more likely to obtain an annual mammogram exam compared to women with no family history of breast cancer (OR=3.95, CI [4.94-9.83], p<0.0001). In contrast to the individual results, in the multivariable model, the obesity status of women was not predictive of a woman’s likelihood to receive breast cancer screening (OR=1.00, CI [0.83-1.19], p=0.8451). Women who smoked regularly had a moderate increase in breast cancer screening use compared to women who did not smoke (OR=1.20, CI [1.04-1.39], p=0.0062). 
With regards to health care utilization, women who had more the more PCP visits were slightly more likely to receive a mammogram compared to women with fewer PCP visits, however, this was not statistically significant (OR=1.02, CI [1.00-1.03], p<0.0684). Women who had more specialist visits were also more likely to receive a mammogram compared to women with fewer specialist visits (OR=1.31, CI [1.25-1.35], p<0.0001). In contrast, women who had fewer inpatient admissions were significantly less likely to be screened compared to women who had higher rates of inpatient admissions (OR=0.71, CI [0.66-0.77], p<0.0001). Women who had more ED visits in a year had a slightly less likely to receive a mammogram compared to women with decreased numbers of ED visits (OR=0.96, CI [0.92, 0.99], p=0.0001). The number of LANE ED visits was not associated with breast cancer screening rates.


Table 10. Results from Model 4 Logistic Regression among Women from a Managed Care Organization (n=6,922). 
Variables (Reference Category)	Measurement	Factor Category	Whole Sample Adjusted Odds Ratio (AOR) (95%)
Socio-demographics			
Age Group (65 – 74 yr)	52 – 58  	Predisposing	0.85 (0.71, 1.03)
	59 – 64 		0.89 (0.74, 1.08)
Race (White)	African American	Predisposing	1.28 (1.12, 1.47)*
	Others		1.30 (1.05, 1.61)*
Ethnicity (Non-Hispanic)	Hispanic	Predisposing	1.88 (1.51, 2.35)*
Area of Residence (Urban)	Rural	Enabling	0.77 (0.68, 0.88)*
Region (Leigh)	Northwest	Enabling	0.93 (0.73, 1.19)
	Southwest		0.73 (0.61, 0.87)*
Individual Health Risk Factors			
Number of Health Conditions (6+)	0 	Need-Related	0.30 (0.21, 0.42)*
	1 – 2 		0.94 (0.81, 1.09)
	3 – 5  		1.01 (0.89, 1.15)
Family History of Breast Cancer (No)	Yes	Predisposing	6.97 (4.94, 9.83)*
Obesity Status (No)	Yes	Need-Related	1.00 (0.83, 1.19)
Smoking Status (No)	Yes	Need-Related	1.20 (1.04, 1.39)*
Health Care Utilization			
Number of PCP Visits		Health Care 	1.02 (1.00, 1.03)
Inpatient Admissions		Health Care	0.71 (0.66, 0.77)*
Number of ED visits		Health Care	0.96, (0.92, 0.99)*
Number of Specialist visits		Health Care	1.31 (1.25, 1.38)*
Number of LANE ED		Health Care	1.00 (0.92, 1.10)
*Significant at p<0.05
4.3	Discussion
In the U.S., early identification of breast cancer via mammography, and subsequent treatment, is associated with a 19% reduction in mortality overall women due to breast cancer, and 32 reduction among 60 year old women  ADDIN EN.CITE [5]. In addition, the costs of treatment are 30-50% lower for early stage breast cancer versus later stages [6]. Although breast cancer screening is a covered benefit by many health insurance programs, including Medicaid, less than 60% of women greater than 50 years old receive a mammogram. The barriers to screening are unclear, especially among women on Medicaid who are served by a managed care organization. To identify predictors of utilization (and non-utilization) of breast cancer screening, I analyzed data on women with Medicaid coverage from a managed care organization in Pennsylvania.
	As expected, variables representing the three categories of factors (predisposing, enabling, and need-related) comprising the Anderson Health Care Utilization Model were significantly associated with utilization of breast cancer screening (Table 10). In addition, several measures of overall health care utilization were associated with breast cancer screening utilization. The specific relationships between these variables and breast cancer utilization are discussed below. 
 	My analyses revealed that three of the four predisposing factors were associated with utilization of breast cancer screening. Members of racial minorities, Hispanics, and women with a family history of breast cancer were more likely to receive breast cancer screening than Caucasian, non-Hispanic women with no family history of breast cancer, but age-group did not differ by screening utilization. The high likelihood of screening given a family history of breast cancer (OR=6.97) is encouraging, because both the CDC and the American Cancer Society recommend that screening commence at an early age due to family history of breast cancer (especially if a mutation is present). These results are consistent with other reports  ADDIN EN.CITE [91-94].
In contrast, the higher likelihood that racial minorities and Hispanics had higher utilization of screening is counter-intuitive. These results may attributed to our analyses of Medicaid data from a managed care organization; to qualify for service, individuals with Medicaid insurance, have a high burden of illness and disability compared to the individuals from the general population. Also, minority groups are more likely to receive care from a government funded organization such as Medicaid, Medicare, and the Department of Veterans Affairs (VA) compared to those who do not qualify for such coverage in the general population [95]. Furthermore, most studies have been done on the general population. Thus, results from this population may differ from reports in the literature that have mostly been done on populations of individuals with private insurance or no insurance. 
In support of our hypothesis that the higher health burden may have influenced our results, analyses revealed that within the study population, women with six or more health conditions were more likely to utilize breast cancer screening and have more PCP visits compared to women who do not utilize the service.  The high frequency of minorities (31%) in our study population were members of minority groups, as well as the increased burden of disease, may partly explain our results. 
In addition to number of health conditions, two other need-related factors, smoking and obesity, were assessed. Smoking was associated with increased utilization of screening, but obesity was not. Smoking is known to be associated with risk of developing breast cancer [96] and women are likely to be informed of this risk by their PCP. Our results indicate that women who utilize screening, visit their PCPs more frequently than non-utilizers, 7.4 versus 4.7 times/year, respectively (Table 8). 
I assessed two enabling factors: urban versus rural, as well as different regions in PA. Consistent with expectation, women living in the Southwestern regions or in rural counties were less likely to utilize screening than their urban counterparts (Table 10). The lower rates of utilization in rural versus urban counties may be due to lack of resources and access. A search was performed  on the American College of Radiology (ACR) website in August 2017 to determine the number of breast cancer screening facilities were in Pennsylvania and in each county (https://www.acraccreditation.org/accredited-facility-search (​https:​/​​/​www.acraccreditation.org​/​accredited-facility-search​)). Breast cancer screening may be performed in 357 accredited facilities in PA. Women in rural counties have access to 19.6 screening centers within 50 miles, compared to women in urban who have access to an aver of 66.7 screening centers within 50 miles. 
In summary, no single factor category or variable from the Health Care Utilization Model was a major determinant for breast care utilization: many variables contribute significantly influenced utilization of breast cancer screening. Analysis of enabling factors (rural residence), indicate that lack of screening centers reduced the likelihood of women utilizing breast cancer screening. Improving access to screening clinics in these areas, or incorporating initiatives to combine screening with PCP visits may improve screening rates. Although minority groups and Hispanics had higher odds of screening (two predisposing factors), the rates were still low, and need to be improved. Two need-related factors (smoking and increased number of health conditions) were associated with increased breast cancer screening, but obesity was not.  The health care utilization variables related to increased contact with a health care physician (PCP or specialist) were associated with increased likelihood of screening, whereas inpatient admissions and number of ED visits were associated with a decrease likelihood. These results may indicate that primary health care physicians (PCP or specialist), may be more likely to educate women regarding the need for screening. Overall, the predisposing factors and enabling factors showed the largest impact (in terms of magnitude of odds ratios) on the likelihood of women to utilize breast cancer screening. 
4.3.1	Future Directions
Future research directions include performing a qualitative study to assess why women are not utilizing breast cancer screening. This study would include collecting qualitative data on perception, health beliefs, culture or values through several means including, but not limited to: focus groups, interviews, and surveys. Another option assess differences in utilization would  include analyzing Medicare data to determine if the breast cancer screening rates, and associated factors, are the same in the Medicare population as they are in the Medicaid population. Because Medicare and Medicaid serve different populations, the associated factors and screening rates are likely to differ. Another direction would be to investigate if breast cancer screening is effective in detecting early stage breast cancer, and thus decreasing mortality and treatment costs and compare these results to those from other organizations as well as screening results from national databases.
4.3.2	Limitations
There are several limitations in the analysis. One limitation is that highly disabled women were not included in the population study. Infrastructure and other resources may prevent highly disabled women from receiving a mammogram, and were not considered in this study. 
In addition, only Medicaid data was assessed. Medicaid and Medicare serve two different populations. Medicare is a federal program that provides health coverage if you are 65 and older or have a severe disability, regardless of income, whereas Medicaid is a state and federal program that provides health coverage for individuals with very low income [79]. The trends for Medicaid data may be very different from the Medicare data because Medicare is primarily for individuals over 65 years of age versus the Medicaid population that encompasses anyone with a low income or a disability. Furthermore, the rates for Medicaid differ from the general population, because the Medicaid population is a non-random sample. 
This dataset does not contain information on whether members switched providers and had received their mammogram at a previous provider before switching. This limit may lead to skewed results of women not receiving an annual mammogram even though they may have received one previously from another provider. 
An additional limitation is the absence of qualitative data available with regards to perception of breast cancer screening, health belief, culture or values. Qualitative data may provide insights as to why women are not utilizing the service and remove some speculation regarding effective interventions.  For example, are PCPs communicating the advantages of breast cancer screening, thus, screening rates are higher among women who visit their PCP more often. 
5.0 	Screening Program Improvements
There are many good things about the screening program at the MCO. The rates of breast cancer screening among women with a family history of breast cancer are high (88%). Women who were also in higher contact with their PCP and specialists were also more likely to receive breast cancer screening. This could be due to the fact that these women are generally sicker than the general population since they are on Medicaid which can be seen in this dataset with the number of health conditions each women has (average = 4.2). African American, minority, and non-Hispanic women were also more likely to receive mammograms than their White counterparts. 
There are several screening program improvements that can be implemented in the MCO based on this research. More outreach can be done to notify women of their eligibility to receive a mammogram. Women are encouraged to begin screening at age 40 years old, however, the MCO only advertises on their website for women to be screened according to HEDIS guidelines (52-74 years old). If screening was advertised to all age-eligible women instead of just HEDIS, women would start and maintain screening at an earlier age than what they currently do. This can be seen in the data from the MCO where no women under the age of 52 were receiving biannual mammogram screenings. 
The MCO could also encourage PCPs and specialists to mention mammograms to their patients since they are coming in contact with this population often. The more than these health care providers mention mammograms to their patients, the more likely these patients are to pursue the screening. Increasing access to screening facilities could also help to improve mammogram rates at the MCO. Since rural women are less likely than urban women to utilize screening and have less screening facilities near them, the MCO can try to increase their advertising of mammogram screenings and offer clinics near rural women who may not have a clinic near them. Transportation may also be an issue for these rural women as they may have to travel further to receive screening than their urban counterparts. By looking at these issues, the MCO would be able to determine the extent of these barriers to their clients and help them better utilize the resources available to them to ensure they are getting their mammograms.
6.0 	Acknowledgements





USPSTF	U.S. Preventive Services Task Force
CDC	Centers for Disease Control and Prevention
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Table 12. Additional Health Conditions Descriptive Characteristics





Atrial Fibrillation	4,406	2,454 (0.6772)	1,952 (0.5919)	<0.0001*
Cardiogenic Shock	4,412	2,457 (0.6780)	1,955 (0.5928)	<0.0001*
Cardiomyopathy	4,408	2,456 (0.6777)	1,952 (0.5919)	<0.0001*
Central Nervous System Disease	199	98 (0.0270)	101 (0.0306)	0.3730
Cerebral Palsy	17	9 (0.0025)	8 (0.0024)	0.9613
Cerebral Vascular Disease	253	138 (0.0381)	115 (0.0349)	0.4772
Chronic Hepatitis 	265 	152 (0.0419)	113 (0.0343)	0.0963
Chronic Obstructive Pulmonary Disease (COPD)	1,133	576 (0.1589)	557 (0.1689)	0.2638
Coagulation Defects	35	16 (0.0044)	19 (0.58)	0.4304
Congestive Heart Failure (CHF)	4,413	2,455 (0.6774)	1,958 (0.5937)	<0.0001*
CHF Additional 	4,410	2,453 (0.6769)	1,957 (0.5934)	<0.0001*
Coronary Artery Disease (CAD)	4,422	2,464 (0.6799)	1,958 (0.5937)	<0.0001*
Cystic Fibrosis** (1 person) 	1	0 (0.00)	1 (0.0003)	0.4765
Defibrillator	56	29 (0.0080)	27 (0.0082)	0.9318
Diabetes Type 1 (DM)	1,968	1,093 (0.3016)	875 (0.2653)	0.0008*
Diabetes Type 2	2,135	1,186 (0.3273)	949 (0.2878)	0.0004*
Diastolic Dysfunction	4,406	2,453 (0.6769)	1,953 (0.5922)	<0.0001*
Edema 	287	159 (0.0439)	128 (0.0388)	0.2913
End Stage Renal Disease (ESRD)	57	27 (0.0075)	30 (0.0091)	0.4491
Epilepsy	2,953	1,627 (0.4490)	1,326 (0.4021)	<0.0001*
Fall Risk	75	39 (0.0099)	39 (0.0118)	0.4477
Hematological Sickle Cell**	4	2 (0.0006)	2 (0.0006)	1.0000
Hemo Strat	0	0 (0.00)	0 (0.00)	--
HIV	88	58 (0.0160)	30 (0.0091)	0.0104*
Hyperlipidemia (Hyperlip)	3,671	2,186 (0.6032)	1,485 (0.4503)	<0.0001*
Hypertension (HTN)	4,633	2,573 (0.7100)	2,060 (0.6246)	<0.0001*
Immune Deficiency 	111	73 (0.0201)	38 (0.0115)	0.0043*
Inflammatory Bowel Disease	86	55 (0.0152)	31 (0.0094)	0.0302*
Liver Disease	253	161 (0.0444)	92 (0.0279)	0.0003*
Lupus Connective Tissue Disorders	3,409	1,924 (0.5309)	1,485 (0.4503)	<0.0001*
Migraine	461	264 (0.0728)	191 (0.0597)	0.0288*
Morbid Obesity (MO)	300	173 (0.0477)	127 (0.0385)	0.0596
Multiple Sclerosis (MS)	58	30 (0.0083)	28 (0.0085)	0.9231
Muscular Dystrophy 	11	6 (0.0017)	5 (0.0015)	0.8842
Myasthenia Gravis**	7	3 (0.0008)	4 (0.0012)	0.6147
Neoplasm Malignant	366	255 (0.0704)	111 (0.0337)	<0.0001*
Osteoarthritis	3,694	2,084 (0.5751)	1,610 (0.4882)	<0.0001*
Table 12. Continued
Variables	All52 – 74 Years(6,922)	Mammogram Users(3,624)	Non-Mammogram Users(3,298)	p-value
Osteoporosis	343	262 (0.0723)	81 (0.0246)	<0.0001*
Pancreatitis Chronic 	19	13 (0.0036)	6 (0.0018)	0.1603
Paralysis	16	5 (0.0014)	11 (0.0033)	0.0906
Parkinson’s Disease	524	293 (0.0808)	231 (0.0700)	0.0896
Prosthetic Valve 	11	5 (0.0014)	6 (0.0018)	0.6465
Renal Disease	256	161 (0.0444)	95 (0.0288)	0.0006*
Rheumatoid Arthritis 	3,426	1,928 (0.5320)	1,498 (0.4542)	<0.0001*
Seizure Strat	230	128 (0.0353)	102 (0.0309)	0.3085
Spina Bifida**	5	0 (0.00)	5 (0.0015)	0.0245*
Spina Bifida SCI	19	6 (0.0017)	13 (0.0039)	0.0694




Valvular Heart Disease	4,415	159 (0.0439)	128 (0.0388)	<0.0001*
Acid Related Disorders RX	3,569	2,069 (0.5709)	1,500 (0.4548)	<0.0001*
Dementia RX	45	24 (0.0066)	21 (0.0064)	0.8951
Glaucoma RX	227	151 (0.0417)	76 (0.0230)	<0.0001*
Gout Hyperuricemia RX	105	59 (0.0163)	46 (0.0139)	0.4278
Pain RX	2,807	1,507 (0.4158)	1,300 (0.3942)	0.0668
Psychological Disorders RX	4,781	2,610 (0.7202)	2,171 (0.6583)	<0.0001*
Psychoses RX	1,618	876 (0.2417)	742 (0.2250)	0.1003
Thyroid Disorders RX	1,304	745 (0.2056)	559 (0.1695)	0.0001*
Tuberculosis RX**	9	5 (0.0014)	4 (0.0012)	1.0000
*Significant at p<0.05







Table 13. Collinearity Test of Variables
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Analysis of Variance: 
Model: DF =14, Sum of Squares = 200.9, Mean Square = 14.3, F value = 64.96, p <0.0001
Error: DF = 6907, Sum of Squares = 1525.8, Mean Square = 0.22
Corrected Total: DF = 6921, Sum of Squares 1,726.7
Root MSE = 0.47000
R2 = 0.1164
Adjusted R2 =0.1146
Coefficient Variable = 98.6

Variance inflation < 5 is considered to have no collinearity.
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